FT Faeth Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Faeth Therapeutics, Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €892m. The latest transaction was filed on 11 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: STEPHENSON BRIAN C. Every trade is openly available.
Analyst consensus: bullish or bearish? Analysts rate Faeth Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$54.64.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 August 2026
All Executives20 Thresholds0 Prospectus0 Other0
Declarations 20 total
● 10% Stockholder · Executives · 22 Jul 2026
130,142 shares @ US$27.99 0.44% mcap 100.0% of flow Common SEC144:0001959173-26-005879
▲ Chief Financial Officer · Executives · 24 Jun 2026
2,891 shares Common Stock SEC:0001780030-26-000005:0
Canonical exit: 22 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 24 Jun 2026
3,000 shares Common Stock SEC:0001780030-26-000005:1
Canonical exit: 22 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 24 Jun 2026
3,400 shares Common Stock SEC:0001780030-26-000005:2
Canonical exit: 22 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 24 Jun 2026
100 shares Common Stock SEC:0001780030-26-000005:3
Canonical exit: 22 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 26 Jun 2026
580 shares Common Stock SEC:0001780030-26-000005:4
Canonical exit: 24 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 26 Jun 2026
4,212 shares Common Stock SEC:0001780030-26-000005:5
Canonical exit: 24 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 26 Jun 2026
1,358 shares Common Stock SEC:0001780030-26-000005:6
Canonical exit: 24 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 26 Jun 2026
100 shares Common Stock SEC:0001780030-26-000005:7
Canonical exit: 24 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 22 Jun 2026
1,797 shares Common Stock SEC:0001780030-26-000004:0
Canonical exit: 20 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 22 Jun 2026
1,118 shares Common Stock SEC:0001780030-26-000004:1
Canonical exit: 20 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 22 Jun 2026
1,583 shares Common Stock SEC:0001780030-26-000004:2
Canonical exit: 20 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 22 Jun 2026
3,329 shares Common Stock SEC:0001780030-26-000004:3
Canonical exit: 20 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 22 Jun 2026
356 shares Common Stock SEC:0001780030-26-000004:4
Canonical exit: 20 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 23 Jun 2026
6,836 shares Common Stock SEC:0001780030-26-000004:5
Canonical exit: 21 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 23 Jun 2026
1,969 shares Common Stock SEC:0001780030-26-000004:6
Canonical exit: 21 Sept 2026 (T+90) ▲ Chief Financial Officer · Executives · 23 Jun 2026
425 shares Common Stock SEC:0001780030-26-000004:7
Canonical exit: 21 Sept 2026 (T+90) ▲ President and CEO · Executives · 22 Jun 2026
2,806 shares Common Stock SEC:0002111813-26-000010:0
Canonical exit: 20 Sept 2026 (T+90) ◇ President and CEO · Executives · 22 Jun 2026
45,252 shares Common Stock SEC:0002111813-26-000010:1
◇ President and CEO · Executives · 22 Jun 2026
8,213 shares Common Stock SEC:0002111813-26-000010:2
About Faeth Therapeutics, Inc. Faeth Therapeutics, Inc. is a company focused on developing innovative therapies for metabolic diseases. It is listed on NASDAQ under the ticker XNAS.